---
layout: post
title: 新冠疫情：印度研制出检测试纸，一小时出结果费用不到7美元
date: 2020-10-05 20:46:44.000000000 +08:00
categories: bbc
---

<main role="main"><div class="GridItemConstrainedLarge-sc-12lwanc-4 gVouae"></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi StyledTimestamp-uounnc-1 ebSCEt"><time dateTime="2020-10-05" class="StyledTimestamp-um718p-0 iENDai">2 小时前</time></div><div class="GridItemConstrainedLargeNoMargin-sc-12lwanc-5 tOkbK"><div class="Figure-sc-6a3dhy-0 gJUCFc"><div class="NestedGridParentLarge-sc-12lwanc-10 hfLVVX"><div class="NestedGridItemChildLarge-sc-12lwanc-9 fkKpIa"><div class="ImagePlaceholder-sc-11u25v2-0 _StyledImagePlaceholder-gu1fm2-0 kvTWeV"><img srcSet="https://ichef.bbci.co.uk/news/240/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg 240w, https://ichef.bbci.co.uk/news/320/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg 320w, https://ichef.bbci.co.uk/news/480/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg 480w, https://ichef.bbci.co.uk/news/624/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg 624w, https://ichef.bbci.co.uk/news/800/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg 800w" alt="Feluda Test" src="https://images.weserv.nl/?url=ichef.bbci.co.uk/news/640/cpsprodpb/CD75/production/_114679525_photo-2020-09-29-12-43-47.jpg" width="976" class="StyledImg-sc-7vx2mr-0 dQLeqZ"/></div></div><div class="NestedGridItemChildLarge-sc-12lwanc-9 ichKJL"><p>印度科学家开发了一种价格低廉的纸质检测新冠病毒的方法，这种方法可以提供类似验孕试纸的快速检测结果。</p></div></div></div></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA"><b>印度科学家开发了一种价格低廉的纸质检测新冠病毒的方法，这种方法可以提供类似验孕试纸的快速检测结果。BBC记者苏蒂克·比斯瓦斯（Soutik Biswas）、克鲁提卡·帕蒂（Krutika Pathi）为您解释这种测试方法的原理。</b></p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">这项测试以印度一名著名的虚构侦探的名字命名，使用的是CRISPR基因编辑技术。科学家们估计，这项叫做费鲁达（Feluda）的检测方法在一小时内就能得到检测结果，花费为500卢布（约合6.75美元）。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">印度塔塔集团将生产费鲁达，它可能是全球首个上市的纸质新冠病毒检测工具。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">印度政府首席科学顾问拉加万（K Vijay Raghavan）教授对BBC表示，这是一项简单、精确、可靠并且价格低廉的测试。</p></div><section aria-label="广告 2" aria-hidden="true" role="region" data-e2e="advertisement" class="AdContainer-sc-8mk8fx-0 itFDSt MpuContainer-uounnc-0 koWnML"><div id="dotcom-mpu" class="dotcom-ad"></div></section><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><div class="Wrapper-e2169q-0 kopXQT"><ul dir="ltr" role="list" class="BulletedList-sc-13z0d8v-0 biIiLh"><li role="listitem" class="BulletedListItem-sc-13z0d8v-1 kHsWph"><a href="https://www.bbc.com/zhongwen/simp/world-54338030" class="InlineLink-hkwpaz-0 idscKS">新冠死亡数超100万 1.2亿检测试剂送往中低收入国家</a></li><li role="listitem" class="BulletedListItem-sc-13z0d8v-1 kHsWph"><a href="https://www.bbc.com/zhongwen/simp/world-54285829" class="InlineLink-hkwpaz-0 idscKS">印度新冠疫情直逼美国 实地情况或比想象更糟</a></li><li role="listitem" class="BulletedListItem-sc-13z0d8v-1 kHsWph"><a href="https://www.bbc.com/zhongwen/simp/world-53892918" class="InlineLink-hkwpaz-0 idscKS">新冠疫情：解读印度的死亡数据与“群体免疫”</a></li></ul></div></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">印度德里的基因组学和综合生物学研究所（Institute of Genomics and Integrative Biology）的研究员开发了这种检测方法，他们与一些私人实验室在约2000名患者中试验了这种检测方法，其中包括那些已经对新冠病毒检测呈阳性的患者。</p></div><div class="GridItemConstrainedLargeNoMargin-sc-12lwanc-5 tOkbK"><div class="Figure-sc-6a3dhy-0 gJUCFc"><div class="NestedGridParentLarge-sc-12lwanc-10 hfLVVX"><div class="NestedGridItemChildLarge-sc-12lwanc-9 fkKpIa"><div class="ImagePlaceholder-sc-11u25v2-0 _StyledImagePlaceholder-gu1fm2-0 kvTWeV"><div class="lazyload-wrapper"><div class="lazyload-placeholder"></div></div><img alt="A paramedic conducts a Rapid Antigen test for COVID-19 of a Kashmiri man in Srinagar" src="https://images.weserv.nl/?url=ichef.bbci.co.uk/news/640/cpsprodpb/ED19/production/_114679606_mediaitem114679605.jpg" width="976" class="StyledImg-sc-7vx2mr-0 dQLeqZ"/><p role="text" class="Copyright-sc-11lgtw-0 hDvIfz"><span class="VisuallyHiddenText-sc-1yjwwa5-0 ldFJPH">图像来源，</span><span lang="en-GB">EPA</span></p></div></div><div class="NestedGridItemChildLarge-sc-12lwanc-9 ichKJL"></div></div></div></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">他们发现新的检测方法灵敏度为96%，特异度为98%。测试的准确性基于这两个数字，一种高度敏感的测试可以检测出几乎所有的患者，而一个高特异度的测试可以正确排除几乎所有没有患病的人。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">第一项数据可以确保不会出现太多假阴性结果，第二项可以确保没有太多假阳性结果。印度医药监管机构已经批准这种测试进行商业使用。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">印度目前有600多万新冠病毒确诊感染病例，为全球第二高的国家。到目前为止，印度有超过10万人死于新冠病毒。</p></div><div class="GridItemConstrainedLargeNoMargin-sc-12lwanc-5 tOkbK"><div class="Figure-sc-6a3dhy-0 gJUCFc"><div class="NestedGridParentLarge-sc-12lwanc-10 hfLVVX"><div class="NestedGridItemChildLarge-sc-12lwanc-9 fkKpIa"><div class="ImagePlaceholder-sc-11u25v2-0 _StyledImagePlaceholder-gu1fm2-0 kvTWeV"><div class="lazyload-wrapper"><div class="lazyload-placeholder"></div></div><img alt="An Indian employee working in a mall, reacts as health worker takes a nasal swab sample to conduct his Rapid Antigen test for Covid-19 inside a mall in Mumbai, India" src="https://images.weserv.nl/?url=ichef.bbci.co.uk/news/640/cpsprodpb/2DB1/production/_114679611_mediaitem114679607.jpg" width="976" class="StyledImg-sc-7vx2mr-0 dQLeqZ"/><p role="text" class="Copyright-sc-11lgtw-0 hDvIfz"><span class="VisuallyHiddenText-sc-1yjwwa5-0 ldFJPH">图像来源，</span><span lang="en-GB">EPA</span></p></div></div><div class="NestedGridItemChildLarge-sc-12lwanc-9 ichKJL"></div></div></div></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">印度目前每天在全国检测约10万份样本，使用两种测试方法。第一种是久经考验的PCR拭子测试，第二种是快速抗原测试。PCR测试一般来说很可靠，但成本达到2400卢比（约合34美元），其假阳性率和假阴性率都很低。抗原测试价格更低廉，在检测阳性感染方面更精确，但比PCR测试发现更多假阴性结果。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">全球健康和卫生政策研究员本班山（Anant Bhan）说，在印度扩大检测并不容易，目前仍需要等待很长时间并且缺乏检测工具，目前印度进行许多快速抗原测试，但存在假阴性问题。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">他相信，费鲁达测试可能会取代抗原测试，因为相对更便宜，也更准确。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">基因组学和综合生物学研究所总监阿加瓦尔（Anurag Agarwal）对BBC表示：“新的测试方法和PCR测试一样可靠，更快速，并且可以在没有精密仪器的更小型实验室进行。”</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">费鲁达试验样本采集类似于PCR测试，将鼻拭子插入鼻子几英寸，以检查鼻道后部的冠状病毒。印度仍然不允许对唾液样本进行新冠病毒检测。</p></div><div class="GridItemConstrainedLargeNoMargin-sc-12lwanc-5 tOkbK"><div class="Figure-sc-6a3dhy-0 gJUCFc"><div class="NestedGridParentLarge-sc-12lwanc-10 hfLVVX"><div class="NestedGridItemChildLarge-sc-12lwanc-9 fkKpIa"><div class="ImagePlaceholder-sc-11u25v2-0 _StyledImagePlaceholder-gu1fm2-0 goxMbj"><div class="lazyload-wrapper"><div class="lazyload-placeholder"></div></div><img alt="Locals wear protective face masks at government test center in Kolkata," src="https://images.weserv.nl/?url=ichef.bbci.co.uk/news/640/cpsprodpb/9EF9/production/_114679604_mediaitem114679533.jpg" width="976" class="StyledImg-sc-7vx2mr-0 dQLeqZ"/><p role="text" class="Copyright-sc-11lgtw-0 hDvIfz"><span class="VisuallyHiddenText-sc-1yjwwa5-0 ldFJPH">图像来源，</span><span lang="en-GB">EPA</span></p></div></div><div class="NestedGridItemChildLarge-sc-12lwanc-9 ichKJL"><p>印度目前有600多万新冠病毒确诊感染病例，为全球第二高的国家。到目前为止，印度有超过10万人死于新冠病毒。</p></div></div></div></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">在传统的PCR检测中，样本要被送到一个认可的实验室，经过一系列“周期”才能恢复足够的病毒。而新的费鲁达测试使用CRISPR基因编辑技术来检测病毒，结果可以在纸上读出，两条蓝色的线就是阳性，一条蓝色的线就是阴性。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">在美国和英国，数家公司和研究实验室在开发类似的检测试纸，因为可以大规模生产，也比较便宜。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">“检测资源仍然有限，我们需要尽一切努力来提高检测，所以费鲁达测试是朝这个方向迈进的重要一步，”哈佛医学院研究员基斯勒（Stephen Kissler）说。</p></div><div class="GridItemConstrainedMedium-sc-12lwanc-2 fVauYi"><p class="Paragraph-k859h4-0 bWtIRA">疫苗对缓解新冠疫情至关重要，但基斯勒指出，可靠、容易获得的检测也是让人们生活恢复正常的关键。</p></div></main>
